Author:
Feng Qian,Huang Zhihao,Song Lei,Wang Le,Lu Hongcheng,Wu Linquan
Abstract
Abstract
Background
The application of molecular targeting therapy and immunotherapy has notably prolonged the survival of patients with hepatocellular carcinoma (HCC). However, multidrug resistance and high molecular heterogeneity of HCC still prevent the further improvement of clinical benefits. Dysfunction of tumor-infiltrating natural killer (NK) cells was strongly related to HCC progression and survival benefits of HCC patients. Hence, an NK cell-related prognostic signature was built up to predict HCC patients’ prognosis and immunotherapeutic response.
Methods
NK cell markers were selected from scRNA-Seq data obtained from GSE162616 data set. A consensus machine learning framework including a total of 77 algorithms was developed to establish the gene signature in TCGA–LIHC data set, GSE14520 data set, GSE76427 data set and ICGC–LIRI–JP data set. Moreover, the predictive efficacy on ICI response was externally validated by GSE91061 data set and PRJEB23709 data set.
Results
With the highest C-index among 77 algorithms, a 11-gene signature was established by the combination of LASSO and CoxBoost algorithm, which classified patients into high- and low-risk group. The prognostic signature displayed a good predictive performance for overall survival rate, moderate to high predictive accuracy and was an independent risk factor for HCC patients’ prognosis in TCGA, GEO and ICGC cohorts. Compared with high-risk group, low-risk patients showed higher IPS–PD1 blocker, IPS–CTLA4 blocker, common immune checkpoints expression but lower TIDE score, which indicated low-risk patients might be prone to benefiting from ICI treatment. Moreover, a real-world cohort, PRJEB23709, also revealed better immunotherapeutic response in low-risk group.
Conclusions
Overall, the present study developed a gene signature based on NK cell-related genes, which offered a novel platform for prognosis and immunotherapeutic response evaluation of HCC patients.
Funder
Science and Technology Research Project of Jiangxi Education Department
Science and Technology Research Project of Jiangxi Provincial Administration of Traditional Chinese Medicine
Natural Science Foundation Project of Jiangxi Provincial Science and Technology Department
Publisher
Springer Science and Business Media LLC
Reference80 articles.
1. E C, D S. Emerging Therapies for Hepatocellular Carcinoma (HCC). Cancers (Basel). 2022;14:8.
2. Laura K, Hashem E-S. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156:477-491.e1.
3. Mc Glynn Katherine A, Petrick Jessica L, El-SeragHashem B. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;8:4–13.
4. Hyuna S, Jacques F, Siegel Rebecca L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
5. An T, Oussama H, Victoria C, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43:13–25.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献